Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Roche Posts a Phase 3 Kidney-Disease Win With Sefaxersen, Setting Up a Fight With Novartis

Roche Holding AG reported positive phase 3 results for sefaxersen, formerly known as IONIS-FB-LRx, in patients with IgA nephropathy, a kidney disease, from the company's IMAGINATION study conducted inPartnershipwith Ionis Pharmaceuticals, Inc.. Jay Garg, M.D., Roche's global head of nephrology, rheumatology, and cardiovascular, said …

Vinay Lochav | 24 September 2026

Eli Lilly Signs Up to USD 3.35 Billion China Biotech Deal With InnoCare Pharma

Eli Lilly and Company signed a discovery collaboration with Beijing-based InnoCare Pharma Limited covering up to five distinct drug targets spanning GLP-1 and obesity-diabetes therapeutics, BTK inhibition, bispecific antibodies, and broader cancer immunology, a breadth of coverage that reflects Lilly's interest in tapping into …

Vinay Lochav | 24 September 2026

Eli Lilly Dominates Medicare's GLP-1 Market With Share Growing Week on Week

Eli Lilly and Company captures roughly 70 percent of the surging Medicare GLP-1 obesity and diabetes drug market, with the program now reaching approximately 700,000 seniors, and CEO David Ricks telling CNBC in an interview the week of September 21, 2026 that the company's …

Vinay Lochav | 24 September 2026

Dollar General Sees Accelerated Trade-Down as Q2 EPS Jumps 33 Percent

Dollar General Corporation reported second-quarter 2026Earnings Per Shareof USD 2.48, up 33 percent year over year and comfortably ahead of the USD 2.00 analysts had expected, withRevenueof USD 11.3 billion and operating profit up 29.2 percent to USD 769 million. Comparable sales grew 3.5 …

Vinay Lochav | 24 September 2026

Home Depot Shares Extend a Persistent Downtrend as Technicals Flash Warning Signs

The Home Depot, Inc. shares have been characterized by chart-based commentary as being in a persistent downtrend, a description suggesting the recent weakness is part of a sustained pattern rather than an isolated pullback tied to a single piece of news. The stock touched …

Vinay Lochav | 24 September 2026

Kroger Fights the K-Shaped Consumer With Price Cuts as CFO Says the Savings Outweigh Investments

The Kroger Co. Chief Executive Officer Greg Foran said plainly that the basket has to come down, adding that not everyone's basket is the same, a direct acknowledgment that the company is actively cutting prices in response to the K-shaped consumer environment in which …

Vinay Lochav | 24 September 2026

Target's Turnaround Shows Traction as Shares Hit a Fresh 52-Week High

Target Corporation shares closed up 3.61 percent at USD 163.96 the day after the company's second-quarterEarningsreport, marking a fresh 52-week high and extending a rally that has pushed the stock up roughly 60 percent since late 2025. A move of this magnitude to a …

Vinay Lochav | 24 September 2026

Enveda Therapeutics Raises USD 311 Million Series E at a USD 2 Billion Valuation

Enveda Therapeutics, an AI-driven drug discovery biotech led by Chief Executive Officer Viswa Colluru, closed a USD 311 million Series E funding round led by Catalio Capital Management, with Iconiq among the other participating investors, valuing the company at USD 2 billion. A raise …

Vinay Lochav | 24 September 2026

Pentagon Funnels USD 47 Million Into Flagship Pioneering Biotechs for Biodefense Research

The Department of War awarded USD 47 million over five years to Apriori Bio and Prologue Medicines, two portfolio companies ofVenture Capitalfirm Flagship Pioneering, under the department's OnTarget program, with the contract structured to include an option for adding further Flagship-backed projects over time. …

Vinay Lochav | 24 September 2026

Immunovant Kills Its Cutaneous Lupus Program After a Phase 2 Miss, Redirects to Graves' Disease

Immunovant, Inc. terminated its cutaneous lupus erythematosus program for IMVT-1402, an FcRn-blocker, after the drug missed its primary endpoint in a phase 2b proof-of-concept trial, even though the data showed some positive trends that fell short of statistical significance for the primary measure. Shares …

Vinay Lochav | 24 September 2026
Support

Hi! How can we help you today?

Loading…